Top Page
Acrux
(Sydney:ACR)
Acrux (ACR) vs. iShares MSCI Australia ETF (EWA)
Acrux Business Overview & Revenue Model
Acrux Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.09M | 8.43M | 1.72M | 1.34M | 1.25M |
| Gross Profit | 1.13M | 1.95M | -4.65M | -7.59M | -3.76M |
| EBITDA | -8.06M | -2.79M | -12.29M | -15.59M | -11.37M |
| Net Income | -5.80M | -764.00K | -9.83M | -12.63M | -9.47M |
Balance Sheet | |||||
| Total Assets | 8.96M | 14.30M | 15.27M | 24.20M | 18.52M |
| Cash, Cash Equivalents and Short-Term Investments | 2.94M | 6.23M | 5.83M | 15.27M | 9.21M |
| Total Debt | 3.70M | 2.35M | 2.08M | 2.23M | 2.40M |
| Total Liabilities | 5.69M | 5.60M | 6.18M | 5.73M | 5.67M |
| Stockholders Equity | 3.28M | 8.70M | 9.09M | 18.47M | 12.85M |
Cash Flow | |||||
| Free Cash Flow | -4.58M | 584.00K | -9.28M | -11.52M | -8.79M |
| Operating Cash Flow | -4.30M | 703.00K | -8.82M | -11.41M | -8.53M |
| Investing Cash Flow | -276.00K | -119.00K | -465.00K | -102.00K | -254.00K |
| Financing Cash Flow | 1.29M | -183.00K | -155.00K | 17.58M | -159.00K |
Acrux Technical Analysis
Acrux Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$6.76M | 60.00 | 2.14% | ― | ― | ― | |
54 Neutral | AU$49.89M | 21.95 | 26.99% | ― | ― | 51.85% | |
50 Neutral | AU$2.51B | 3.43 | -57.47% | 2.67% | 36.73% | 13.67% | |
42 Neutral | AU$10.08M | ― | -180.09% | ― | ― | 28.57% | |
40 Underperform | $7.37M | ― | -132.58% | ― | -92.98% | -741.67% | |
37 Underperform | AU$8.93M | ― | -80.47% | ― | -41.19% | 20.93% |
Acrux Corporate Events
Acrux Limited has received a $0.46 million advance from Radium Capital as part of its FY25 R&D Tax Incentive, bringing the total advances to $2.19 million. This funding provides early access to the RDTI rebate, which will support the development of products and management of working capital, highlighting Acrux’s strategic use of financial resources to bolster its operations.
Acrux Limited has announced the quotation of 1,500,000 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective July 3, 2025. This move follows the cessation of transfer restrictions on securities previously issued under an employee incentive scheme, potentially enhancing liquidity and shareholder value.
Acrux Limited has experienced a change in the substantial holding of its shares by Phillip Asset Management Ltd, acting for BioScience Managers Translation Fund I. The voting power of Phillip Asset Management Ltd has decreased from 10.32% to 9.21% due to the dilution of holdings caused by the issuance of new shares. This change reflects a shift in the ownership structure of Acrux Limited, which could impact its strategic decisions and stakeholder interests.
Acrux Ltd has announced the appointment of John Warmbrunn as a director effective from June 1, 2025. The Initial Director’s Interest Notice reveals that Mr. Warmbrunn currently holds no securities or relevant interests in the company, indicating a fresh start in his new role without prior financial ties to Acrux.
Acrux Ltd has announced a change in the interest of its director, Don Brumley, who has increased his holdings by acquiring 448,334 ordinary shares through the exercise of vested unlisted rights issued in 2024. This change reflects a strategic move by the director to increase his stake in the company, potentially signaling confidence in Acrux’s future performance and aligning his interests more closely with those of the shareholders.
Acrux Limited has announced the quotation of 448,334 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 23, 2025. This move follows the cessation of transfer restrictions on securities previously issued under an employee incentive scheme. The announcement indicates a strategic step in Acrux’s financial operations, potentially enhancing its market liquidity and providing more investment opportunities for stakeholders.
Acrux, in partnership with TruPharma, has launched Dapsone 7.5% Gel in the United States, a topical prescription medicine for treating acne vulgaris in children aged 9 and older. This product is uniquely marketed in a tube presentation, differentiating it from competitors’ pump bottle packaging, and is manufactured in the U.S. The launch underscores Acrux’s strategic capability to develop and commercialize its pharmaceutical pipeline, with the U.S. market for similar products generating over $43 million in sales annually.
Acrux Limited has announced the appointment of John Warmbrunn as the new CEO and Managing Director, effective June 1, 2025, following the retirement of Michael Kotsanis. Warmbrunn brings over 25 years of experience in the healthcare sector, with a strong track record in international business growth and leadership roles at companies like Ego Pharmaceuticals and Bendigo Community Telco. His appointment is expected to drive Acrux’s next phase of growth, particularly in expanding its international market presence.
Acrux Limited has reported significant growth in product-based revenue following the successful launch of new products in late 2024 and early 2025. The company raised $3.989 million through a placement and share purchase plan, and secured $1.729 million in short-term funding from Radium Capital. These financial activities, coupled with the positive market reception of their products, position Acrux to achieve its strategic goal of sustaining future product development.